Pediatricians and pediatric dermatologists from around the world are gathering in Buenos Aires, Argentina, April 8-11 for the 15th World Congress of Pediatric Dermatology (WCPD 2025). What better place to talk about the science behind the Kenvue platform of iconic pediatric skincare brands and their evolving science for every stage of childhood? The Company will share brand new findings on baby skin conditions ranging from sensitive skin to eczema, and how to best care for these skin types.
“We never stop advancing the science of skincare for the tiniest patients. That’s why we’re showcasing findings from our latest studies, including ways to improve infants’ fragile skin barrier and diminish the physical and emotional impacts of eczema,” said Karina Ribeiro, Global Head of R&D, Essential Health at Kenvue. “Kenvue will also host a panel of globally renowned experts to discuss infant skin care and bathing, with best practices from around the world. It’s part of our commitment to helping pediatricians determine the right skin care for their patients during those key stages of development.”
The symposium, “Dear Doctor: Advice on Skin Care and Bathing Essentials from Birth” will be held on Tuesday, April 8 from 12:30 – 2:00 p.m. in Room F of the Centro de Convenciones Buenos Aires. A panel of experts including Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital, Arun Inamadar, MD, Professor at Shri B. M. Patil Medical College Hospital and Research Centre, Ana Mósca, MD, Associate Clinical Professor of Pediatric Dermatology at Hospital Municipal Jesus, and Mauricio Torres-Pradilla, MD, Professor at Foundation University of Health Sciences, will discuss the latest research and best practices for bathing, moisturizing, and managing sensitive skin in babies. Spanish translation will be provided.
In three brand-new scientific studies authored by Gabrielle Kosmoski, Kenvue R&D Baby Claims & Clinical Manager, the company focuses on essential skincare for infants, including sensitive skin:
- Baby Gentle Wash & Moisturizing Lotion Newborn Routine: Improves Skin Condition and Positively Impacts Skin Barrier, Microbiome, & Bonding, poster #732 — Newborns’ skin barrier is vulnerable to dryness and irritation. Over the course of 4 weeks, a gentle wash and lotion routine improved irritation, dryness, overall skin appearance, and skin pH.
- Baby Eczema Regimen Provides Clinical Eczema Improvement and Skin Benefits in subjects with Mild to Moderate Eczema, poster #728 — For babies, eczema’s effects are both physical and emotional. Products with colloidal oat helped improve the skin condition of babies of all skin tones/types with mild to moderate eczema. Eczema severity, eczema lesions, skin hydration, and skin barrier function were improved, as were babies’ overall comfort and mood.
- Clinical Improvement in Moisturization and Skin Moisture Barrier of an Emollient-Rich Balm Compared to a Lotion and Cream, poster #723 — Early emollient use is critical for baby’s skin development. A thick, emollient-rich balm with oat improved moisturization and barrier function better than a lotion and cream, while acting as a protective layer reducing trans-epidermal water loss and fortifying the skin barrier.
To learn more about the research or schedule interviews, please contact Kenvue R&D media relations.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding new findings on skincare for infants. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
R&D Media Relations
Meghan Harding
MHardin1@kenvue.com